Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467621 | 0.78 | TRPV1 (0.45) | CYP3A4TRPV1 | |
| SCHEMBL2723343 | 0.77 | TRPV1 (0.49) | CYP3A4TRPV1PHGDH | |
| SCHEMBL2723340 | 0.77 | TRPV1 (0.49) | CYP3A4TRPV1PHGDH | |
| SCHEMBL2723345 | 0.77 | TRPV1 (0.42) | CYP3A4TRPV1AVPR1ACCR5PHGDH | |
| SCHEMBL19032342 | 0.72 | TRPV1 (0.55) | TRPV1CCR5 | |
| SCHEMBL15310768 | 0.69 | MAPT (0.38) | TRPV1 | |
| SCHEMBL5405805 | 0.68 | TRPV1 (0.61) | TRPV1PHGDH | |
| SCHEMBL2723773 | 0.68 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL19946461 | 0.68 | TRPV1 (0.50) | TRPV1CCR5 | |
| Trifluoroacetic Acid SCHEMBL5732367 | 0.68 | TRPV1 (0.74) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135423-A1 | E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain | MERCK SHARP & DOHME LTD. (GB) | 2007-06-14 | — | — | US | disclosed |
| EP-1682141-A1 | 4-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LTD. (GB) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005051390-A1 | E-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135423-A1 | E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain | OPRL1, HVCN1, TRPV1 | CYP3A4 1886/4885TRPV1 3/4885AVPR1A 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.